UroGen CFO Degnan buys 2,281 shares
UroGen Pharma CFO Chris Degnan reported an acquisition of 2,281 shares in the company. The Form 4 shows the net acquired amount and a transaction price of $36.69 per share.
69 $80,791 NET ACQUIRED 2,281 OWNERSHIP: 4,561 (Direct) * - Insiders can surrender shares back to the company to pay taxes or cover the cost of an option exercise or vesting. com. com. The Form 4 is filed with the Securities and Exchange Commission by insiders to report transactions in their companies' shares.
Open market purchases and sales must be reported within two business days of the transaction. com or 301-913-5100) (END) Dow Jones Newswires October 09, 2026 12:58 ET (16:58 GMT) The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.